Market
How many UK hospitals will adopt Nyxoah's Genio device by end of 2025?
2
Resolution / Starting Odds
Less than 50 hospitals • 25%
50 to 100 hospitals • 25%
101 to 200 hospitals • 25%
More than 200 hospitals • 25%
Reports from UK healthcare institutions or Nyxoah
Story
Nyxoah Launches App-Controlled Genio Device in UK for Sleep Apnoea Relief, Fitting First Patients
Dec 13, 2024, 09:57 AM
Nyxoah has announced the commercial launch of its innovative therapy, Genio, in the United Kingdom. This new app-controlled nerve stimulator aims to provide relief for millions suffering from sleep apnoea. The device works by stimulating the nerves in the tongue, helping patients breathe more easily during the night. The first patients in the UK have already been fitted with this microchip, marking a significant advancement in the treatment options available for sleep apnoea. This development is expected to bring relief not only to patients but also to their partners, who often endure the effects of snoring associated with the condition.
View original story
Similar markets
0-50 hospitals • 25%
More than 150 hospitals • 25%
101-150 hospitals • 25%
51-100 hospitals • 25%
Less than 200 • 25%
More than 600 • 25%
200 to 400 • 25%
400 to 600 • 25%
Johns Hopkins Hospital • 25%
Mayo Clinic • 25%
Other • 25%
Cleveland Clinic • 25%
100,000 to 150,000 • 25%
Less than 100,000 • 25%
More than 220,000 • 25%
150,001 to 220,000 • 25%
21-30 • 25%
31 or more • 25%
0-10 • 25%
11-20 • 25%
100 to 200 • 25%
Less than 100 • 25%
More than 300 • 25%
200 to 300 • 25%
1 to 2 international approvals • 25%
No international approvals • 25%
3 to 4 international approvals • 25%
5 or more international approvals • 25%
3-4 • 25%
0 • 25%
5 or more • 25%
1-2 • 25%